Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kay Seden

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Current Opinion in HIV and AIDS|October 18, 2011
Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactionsKay Seden, David Back
The Journal of Antimicrobial Chemotherapy|April 29, 2009
Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageableKay Seden, David Back, Saye Khoo
Current Opinion in HIV and AIDS|June 2, 2017
Drug interactions and the role of pharmacokinetic trials in guiding choices in first-line HIV therapy in low-income and middle-income countriesKay Seden, Marta Boffito, Saye Khoo
The Journal of Antimicrobial Chemotherapy|March 26, 2010
New directly acting antivirals for hepatitis C: potential for interaction with antiretroviralsKay Seden, David Back, Saye Khoo
Drugs|December 15, 2010
Grapefruit-drug interactionsKay Seden, Laura Dickinson, Saye Khoo, et al.
In Silico Pharmacology|December 16, 2014
Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenzMarco Siccardi, Adeniyi Olagunju, Kay Seden, et al.
The Journal of Antimicrobial Chemotherapy|August 8, 2018
High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg dailyKay Seden, Daniel Kiiza, Eva Laker, et al.
Clinical Pharmacokinetics|March 13, 2013
Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approachMarco Siccardi, Catia Marzolini, Kay Seden, et al.
The Journal of Antimicrobial Chemotherapy|August 24, 2012
Global patient safety and antiretroviral drug-drug interactions in the resource-limited settingKay Seden, Saye H Khoo, David Back, et al.
Plos One|March 24, 2017
Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infectionKay Seden, Sara Gibbons, Catia Marzolini, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Opinion in HIV and AIDS|October 18, 2011
Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactionsKay Seden, David Back
The Journal of Antimicrobial Chemotherapy|April 29, 2009
Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageableKay Seden, David Back, Saye Khoo
Current Opinion in HIV and AIDS|June 2, 2017
Drug interactions and the role of pharmacokinetic trials in guiding choices in first-line HIV therapy in low-income and middle-income countriesKay Seden, Marta Boffito, Saye Khoo
The Journal of Antimicrobial Chemotherapy|March 26, 2010
New directly acting antivirals for hepatitis C: potential for interaction with antiretroviralsKay Seden, David Back, Saye Khoo
Drugs|December 15, 2010
Grapefruit-drug interactionsKay Seden, Laura Dickinson, Saye Khoo, et al.
In Silico Pharmacology|December 16, 2014
Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenzMarco Siccardi, Adeniyi Olagunju, Kay Seden, et al.
The Journal of Antimicrobial Chemotherapy|August 8, 2018
High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg dailyKay Seden, Daniel Kiiza, Eva Laker, et al.
Clinical Pharmacokinetics|March 13, 2013
Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approachMarco Siccardi, Catia Marzolini, Kay Seden, et al.
The Journal of Antimicrobial Chemotherapy|August 24, 2012
Global patient safety and antiretroviral drug-drug interactions in the resource-limited settingKay Seden, Saye H Khoo, David Back, et al.
Plos One|March 24, 2017
Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infectionKay Seden, Sara Gibbons, Catia Marzolini, et al.
Pageof 2